Pharmaceuticals

SYNERGY

SYNERGY released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 184.39 M, actual EPS CNY 0.0447

SYNERGY released FY2025 Annual Earnings on April 28 After-Market (BJT), actual revenue CNY 828.66 M (forecast CNY 804 M), actual EPS CNY 0.174 (forecast CNY 0.27)

SYNERGY released FY2025 Q4 earnings on April 28 After-Market (BJT), actual revenue CNY 192.42 M, actual EPS CNY -0.0251

SYNERGY FY2026 Q1 Earnings Release Scheduled for April 29 After-Market BJT

SYNERGY to Release FY2025 Earnings on April 29 After-Market (BJT), Forecast Revenue CNY 804 M, EPS CNY 0.27

SYNERGY released FY2025 9 Months earnings on October 24 After-Market BJT, actual revenue CNY 636.24 M, actual EPS CNY 0.1992

SYNERGY released FY2025 Q3 earnings on October 24 After-Market BJT, actual revenue CNY 208.82 M, actual EPS CNY 0.0599

SYNERGY to Release FY2025 Q3 Earnings on October 25 After-Market (BJT)

SYNERGY released FY2025 Q2 earnings on August 28 After-Market BJT, actual revenue CNY 240.52 M, actual EPS CNY 0.0897

SYNERGY released FY2025 Semi-Annual Earnings on August 28 After-Market (BJT), actual revenue CNY 427.42 M, actual EPS CNY 0.1393

SYNERGY to Release FY2025 Semi-Annual Earnings on August 29, 2025 (BJT)

Tonghe Pharmaceutical Receives 'Buy' Rating, Stock Price Rises

Tonghe Pharmaceutical Obtained Certificate for Edoxaban Tosilate in South Korea

Tonghe Pharmaceutical Secretary Responds to Investor Questions on Market Expansion and Fund Recovery

Tonghe Pharmaceutical Responds to Investor Queries on US Export Business

Tonghe Pharmaceutical Increases Investment in Hangzhou Boya to 24.9285%

Tonghe Pharmaceutical Q1 2025 Net Profit Down by 52.30%

SYNERGY released FY2025 Q1 earnings on April 24 After-Market BJT with actual revenue of CNY 186.9 M and EPS of CNY 0.0495

SYNERGY released FY2024 annual earnings on April 24 After-Market BJT, actual revenue CNY 758.89 M (forecast CNY 805.5 M), actual EPS CNY 0.2538 (forecast CNY 0.3466)

SYNERGY released FY2024 Q4 earnings on April 24 After-Market (BJT), actual revenue CNY 188.96 M, actual EPS CNY 0.0258

300636

SYNERGY underwent a cGMP on-site inspection by the U.S. FDA from August 4 to August 7, 2025, covering six major systems: quality system, materials, production, packaging and labeling, equipment facilities, and laboratory controls. The company recently confirmed that it has passed the inspection and complies with the U.S. FDA's cGMP management standards

Zhitong

SYNERGY passed the on-site inspection by the U.S. FDA

According to the Zhitong Finance APP, SYNERGY announced that the company recently received the revised Certificate of Suitability (CEP) for the active pharmaceutical ingredient Ticagrelor issued by the European Directorate for the Quality of Medicines (EDQM). The main reason for this change is the addition of a new production workshop, and the certification scope is: Ticagrelor active pharmaceutical ingredient. The revised certificate will take effect from September 12, 2025

SYNERGY has obtained the European Pharmacopoeia Adaptation Certificate

SYNERGY stated in an institutional survey that the company's CMO/CDMO business saw growth in the second quarter, with promising prospects for the future. In recent years, the company has added more projects in the CMO/CDMO sector. As some older projects gradually exit the market, the company will actively serve existing projects and vigorously explore new projects, striving for new projects to ramp up production as soon as possible to make up for the gap caused by the decrease in orders from existing older projects. The CMO/CDMO business is expected to achieve rapid growth in 2027 and 2028

SYNERGY: CMO/CDMO business is expected to achieve rapid growth in 2027 and 2028

SYNERGY announced that its raw material drug, Mesalazine Potassium, has passed the GMP compliance inspection, which is beneficial for the company to expand the sales of its products in the domestic market, forming a good pattern of simultaneous sales in both domestic and foreign markets. Mesalazine Potassium is suitable for the treatment of adult primary hypertension

SYNERGY: The raw material drug Amlodipine Besylate has passed the GMP compliance inspection

According to the Zhitong Finance APP, SYNERGY announced that the company recently received the drug registration certificates for Agomelatine and Opicapone issued by the Ministry of Food and Drug Safety (MFDS) of South Korea

SYNERGY: Agomelatine and Opicapone have obtained drug registration certificates in South Korea

600458

688206

601956

688511

688265

On June 27, a total of 12 listed companies had their restricted shares unlocked, with a total market value of approximately 7.717 billion yuan. The specific situation of the restricted share unlock today is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlocked Shares TMT 600458 Equity Incentive Restricted Circulation 679,800 DONPER GROUP 601956 Equity Incentive Restricted Circulation 3,103,800 SYNERGY 300636 Equity Incentive Restricted Circulation 1,570,000 Shandong Glass Fiber 605006 Equity Incentive Restricted Circulation 330,900 Aoni Electronics 301189 Extended Restricted Lock-up Period Circulation 7,372,000 Biyih Shares 603215 Equity Incentive Restricted Circulation 15,500 Tianwei Electronics 688511 2,595,000 SMOC 688265 28,575,000 Tonglian Precision 688210 5,285,500 PRIMARIUS 688206 625,700 Ankai Micro 688620 39,200 Huafeng Technology 688629 34,574,000

PRIMARIUS

DONPER GROUP

Sichuan Tianwei Electronics

SMOC

ANYKA MICROELECTRONICS

BIYI

Huafeng

aoni

Union Precision

Zhitong A-shares lock-up release overview | June 27

According to the Zhitong Finance APP, SYNERGY announced that the company recently received the drug registration certificate for tolvaptan from the Ministry of Food and Drug Safety (MFDS) of South Korea. Tolvaptan is an oral anticoagulant primarily used for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment or prevention of deep vein thrombosis and pulmonary embolism

SYNERGY: Tofisopam has obtained the drug registration certificate in South Korea

ALLPACK INDONESIA 2025, an international exhibition, will take place from October 21-24, 2025, at Jakarta International Expo. Supported by Krista Exhibitions and the Indonesian Embassy in Italy, the event aims to strengthen Indonesia-Italy industrial collaboration, showcasing innovations in packaging, plastics, processing, printing, recycling, and pharmaceuticals. With over 1,500 exhibitors and 80,000 visitors expected, it highlights the growing demand for Italian technologies in Indonesia, which saw a 27.23% increase in imports from Italy in 2023. The exhibition will also feature business matching opportunities and seminars to promote sustainable partnerships.

prnewswire

Packaging Corp of America

01:00 ET
			
			
				ALLPACK INDONESIA 2025: Featuring Innovations in Packaging, Plastics, Processing, Printing, Recycling & Pharmaceuticals, Strengthening Indonesia- Italy Synergy in Innovation and Sustainability

SYNERGY released its Q1 2025 performance report, with operating revenue of 187 million yuan, a year-on-year decrease of 9.47%. The net profit attributable to the parent company was 20.7814 million yuan, a year-on-year decline of 52.30%; the net profit after deducting non-recurring gains and losses was 17.6806 million yuan, a year-on-year decrease of 56.33%. The basic earnings per share were 0.0495 yuan

SYNERGY released its first-quarter performance, with a net profit attributable to the parent company of 20.7814 million yuan, a decrease of 52.30%

SYNERGY plans to increase its investment in Hangzhou Boya Biopharmaceutical Co., Ltd. by 11 million yuan, raising its shareholding ratio to 24.9285%. Among this, 1.0581 million yuan will be included in the registered capital, and 9.9419 million yuan will be included in the capital reserve. After the capital increase is completed, Hangzhou Boya's registered capital will change to 8.6571 million yuan. This transaction is a related party transaction and needs to be submitted for review by the shareholders' meeting

CNI BIOMEDICINE

SYNERGY: Plans to increase its investment in Hangzhou Boya by 11 million yuan, raising its shareholding ratio to 24.9285%

SYNERGY(300636.SZ)